|Awarded On||August 21, 2019|
|Title||Discovery and development of novel peptibody-drug conjugate for treating cancers of the digestive system|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Qingyun Liu|
|Cancer Sites||Colorectal, Gallbladder, Liver and Intrahepatic Bile Duct, Stomach|
Cancers of the digestive system, including colorectal, liver, and stomach cancer, represent major types of cancer with high morbidity and mortality in Texas and the rest of the world. In particular, liver cancer is becoming increasingly more common in this state with few treatment options available. This project is aimed at creating a novel class of therapeutics that targets a group of receptors with increased levels in cancers of the digestive system. LGR4, 5, and 6 (leucine-rich repeat containing, G protein-coupled receptor 4, 5, 6) are three related proteins with critical roles in tumor formation and metastasis. Aberrant activation of the three receptors has been shown to drive canc...